Many therapeutics need access to the interiors of cells, where the machinery of life is busy going about its tasks. Historically, reaching the interior of cells with therapeutic molecules has been a recalcitrant problem.

NanoSyrinx is a discovery stage synthetic biology company developing a novel system based around naturally occurring ‘nanosyringes’, to overcome this challenge by delivering therapeutic proteins and peptides direct to the cytosol in a targeted manner.


The company was founded in 2020 by Dr. Joe Healey, Dr. Nick Waterfield and Dr. Alexia Hapeshi to commercialise the groundbreaking nanosyringe technology discovered in the Waterfield Group based at the University of Warwick’s Medical School.

NanoSyrinx is backed by Octopus Ventures, MVentures, IQ Captial, Meltwind, BioCity, & UKI2S.